<DOC>
	<DOCNO>NCT01625156</DOCNO>
	<brief_summary>This phase I trial study side effect best dose tivantinib give combination temsirolimus treat patient solid tumor spread part body remove surgery . Tivantinib temsirolimus may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Tivantinib Temsirolimus Treating Patients With Solid Tumors That Metastatic Can Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) ARQ197 ( tivantinib ) combination temsirolimus adult subject advance solid tumor extensive cytochrome P450 , family 2 , subfamily C , polypeptide 19 ( CYP2C19 ) metabolizers . SECONDARY OBJECTIVES : I . To characterize tolerability and/or MTD ARQ 197 combination temsirolimus adult subject poor CYP2C19 metabolizers ( CYP2C19*2/*2 , *2/*3 *3/*3 polymorphism ) . II . To identify pharmacokinetic parameter ARQ 197 single dose steady state extensive poor CYP2C19 metabolizers . III . To assess steady state pharmacokinetics ARQ 197 alone combination temsirolimus . IV . To determine impact cytochrome P450 , family 3 , subfamily A , polypeptide 4/cytochrome P450 , family 3 , subfamily A , polypeptide 5 ( CYP3A4/5 ) polymorphisms ARQ 197 pharmacokinetic parameter . V. To determine pharmacokinetics temsirolimus active metabolite sirolimus combination ARQ 197 compare historical pharmacokinetic data . VI . To determine impact CYP3A4/5 polymorphisms temsirolimus pharmacokinetic parameter . VII . To describe dose-limiting toxicity determine safety profile combination ARQ 197 temsirolimus . VIII . To evaluate preliminary anti-tumor activity ARQ197 temsirolimus patient advance solid tumor . IX . To correlate archived tumor tissue expression c-Met objective response ARQ 197 temsirolimus therapy . OUTLINE : This dose-escalation study tivantinib . Patients receive tivantinib orally ( PO ) twice daily ( BID ) temsirolimus intravenously ( IV ) 30 minute day 1 , 8 , 15 , 22 ( day 8 , 15 , 22 , 29 course 1 ) . Courses repeat every 28 day ( 35 day course 1 ) absence disease progression unacceptable toxicity . After completion study treatment , patient follow least 4 week .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must histologically confirm solid malignancy ( exclude lymphoma ) metastatic unresectable standard curative palliative systemic therapy ( chemotherapy , target therapy immunotherapy ) exist longer effective Patients must measurable evaluable disease , define Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 No prior treatment temsirolimus agent specifically target meet protooncogene ( cMet ) Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy great 12 week Hemoglobin &gt; = 9.0 g/dL Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin = &lt; 1.5 X institutional upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; institutional upper limit normal Serum creatinine = &lt; institutional upper limit normal creatinine clearance ( either estimate calculate ) &gt; = 60 mL/min/1.73 patient creatinine level institutional normal Fasting glucose = &lt; 150 mg/dL Fasting cholesterol level &lt; 350 mg/dl Fasting triglycerides = &lt; 300 mg/dl Phosphorus &gt; = institutional low limit normal ( repletion allow ) Patients treat , stable brain metastasis allow enroll ; patient must least 4 week radiation medication use treat brain metastasis include steroid ; patient allow antiepileptic medication metabolize cytochrome P450 3A4 2C19 ; patient brain metastasis must stable brain image within 4 week prior start study Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation 3 month discontinuation study drug ; men treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion ARQ 197 administration ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately Ability understand willingness sign write informed consent document Any following : Chemotherapy = &lt; 3 week prior enter study ( 6 week nitrosoureas mitomycin C ) Radiotherapy , endocrine therapy target therapy malignancy = &lt; 2 week prior registration Patients recover ( = &lt; grade 1 ) adverse event due agent administer 4 week earlier ( tolerable grade 2 adverse event may allow discretion investigator ; diarrhea must grade 1 low without schedule use antidiarrheal medication ) Prior anticancer therapy mammalian target rapamycin ( mTOR ) inhibitor ( everolimus , temsirolimus , desferolimus ) agent specifically target cMet Patients receive investigational agent Patients may clinically symptomatic hypothyroidism ; test require eligibility History allergic reaction attribute compound similar chemical biologic composition ARQ 197 temsirolimus ARQ 197 sensitive substrate 2C19 3A4 , strong inhibitor 2C19 moderate inhibitor vitro data 3A4 ; temsirolimus sensitive substrate CYP 3A4 weak inhibitor CYP2D6 CYP3A4/5 ; per UWinRx Drug Interaction Policy , follow medication contraindicate must use caution Contraindicated : CYP2C19 sensitive substrate ( unless close monitoring labs drug level dose adjustment feasible ) , inducer , moderate/strong inhibitor CYP2C19 ; patient take concurrent medication ineligible unless switched alternative medication prior initiation study CYP3A4/5 inducer moderate/strong inhibitor CYP3A4/5 ; patient take concurrent medication ineligible unless switched alternative medication prior initiation study Use caution : CYP2C19 nonsensitive substrate narrow therapeutic window weak inhibitor permit acceptable alternative available determine treat physician ; however , caution use ; consider monitor labs drug level dose adjustment medication feasible ; nonsensitive substrate allow study CYP3A4/5 sensitive substrate nonsensitive substrate narrow therapeutic window weak inhibitor permit acceptable alternative available determine treat physician ; however , caution use ; consider monitor labs drug level dose adjustment medication feasible ; nonsensitive substrate allow study CYP2D6 inducer , moderate/strong inhibitor sensitive substrate permit acceptable alternative available ; however , caution use ; nonsensitive substrate weak inhibitor CYP2D6 allow study History congestive heart failure define class II IV per New York Heart Association ( NYHA ) classification ; active coronary artery disease ( CAD ) ; clinically significant bradycardia ( &lt; 50 beat per minute [ bpm ] ) uncontrolled , cardiac arrhythmia define &gt; = grade 3 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.0 , uncontrolled hypertension ( determined investigator ) ; myocardial infarction occur within 6 month prior study entry ( myocardial infarction occur &gt; 6 month prior study entry permit ) Patients uncontrolled diabetes ( determined investigator ) ; wellcontrolled diabetic patient fast glucose &lt; 150 eligible stable dos medication diabetes least 4 week prior study entry Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude ; breastfeed discontinue mother treat study Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible Patients malabsorption syndrome condition would interfere intestinal absorption pill ; patient must able swallow pill</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>